Gapping up
In reaction to earnings/guidance:
- LOGI +18.1%, CCK +7% (also to initiate a dividend), UBS +6.9%, NGVT +4.9%, ACI +4.2%, IQV +3.6%, CNTG +2.7%, TRV +2.6%, RF +2.5%, PNR +1.8%, CMA +1.6%, CDNS +1.5%, GPK +1.3%, PG +1.3%, BXS +1.2%, MDT +1.1%
Other news:
- APTX +109% (reports "positive" top-line data from Phase 2 study of NYX-783)
- CARA +18.1% (Cara Therapeutics and Vifor Pharma sign US license agreement for IV Korsuva)
- HTZ +10.7% (names new Chief Accounting Officer)
- OESX +6.1% (secures approx. $41 mln in contract extensions)
- IVA +5.6% (FDA grants Fast Track designation to odiparcil)
- ORIC +3.1% (enters into exclusive license agreement with Voronoi)
- XPEV +3% (completed the production of 10,000 units of the P7 smart EV sedan, its flagship model)
- WHR +2.8% (increases quarterly dividend by 4%)
- ACIW +1.9% (Starboard Value discloses 9% stake)
- LAC +1.8% (provides corporate update; establishes US$100 mln at-the-market equity program)
- ZEN +1.7% (adds Instragram for businesses to its customer support offering)
- BLU +1.3% (prices offering of 15,555,556 common shares at $2.25 per common share)
- MDT +1.1% (announces statistically significant 12-month results from a large, multicenter randomized controlled trial)
Analyst comments:
- PLAY +7.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- RYAM +4.4% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- IHG +4.3% (upgraded to Buy from Neutral at Goldman)
- WDAY +2.8% (upgraded to Overweight from Neutral at Piper Sandler)
- FTNT +2.5% (upgraded to Buy from Neutral at Goldman)
- BC +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- OGE +0.9% (upgraded to Neutral from Sell at Goldman)
- FIZZ +0.7% (upgraded to Hold from Underperform at Jefferies)